Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
There is a growing body of data suggesting that the the risk of developing multiple myeloma, or myelomagenesis, is associated with genetic alterations occurring in the tumor cells. A limited number of candidate genes and polymorphisms have been reported in patients with this disease. In this study the investigators will compare the genetic information obtained on purified abnormal plasmocytes obtained from patients with multiple myeloma with available public databases in an effort to identify and if possible validate the role of certain mutations and/or polymorphisms in myelomagenesis. Plasmocytes will be obtained by immunomagnetic enrichment using CD138+ beads.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients with a diagnosis of multiple myeloma | This study will involve a single patient group, namely patients with a diagnosis of multiple myeloma diagnosed by a bone marrow aspirate with cytological analysis of the bone marrow smear.Bone marrow samples obtained during the routine follow-up will undergo plasmocyte enrichment using immunopurification using CD138+ beads and nucleic acids will be extracted for sequencing. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DNA sequencing | Genetic | The aim of this study is to perform DNA sequencing on abnormal plasmocytes obtained from patients with multiple myeloma, in order to identify alterations which are associated with the existence of this disease. DNA analyses will be performed in a single experiment once all samples have been collected. |
| Measure | Description | Time Frame |
|---|---|---|
| DNA mutations associated with the existence of multiple myeloma | DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases. | baseline, pre-intervention/procedure/surgery |
| DNA mutations associated with the existence of multiple myeloma | DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases. | during the intervention/procedure/surgery |
| DNA mutations associated with the existence of multiple myeloma | DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases. | immediately after the intervention/procedure/surgery |
| DNA mutations associated with the existence of multiple myeloma | DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases. | at 1 year |
| DNA mutations associated with the existence of multiple myeloma | DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases. | up to 24 weeks |
| DNA mutations associated with the existence of multiple myeloma | DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases. | through study completion, an average of 1 year |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
- none
Not provided
Not provided
Not provided
Patient samples will be accrued from Intergroupe Francophone du Myélome (IFM) centers in France, in the context of primary care clinics. The investigators aim to collect up to 1,000 samples.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Charles DUMONTET, Pr | Contact | 04 78 46 83 40 | +33 | charles.dumontet@chu-lyon.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospices Civils de Lyon | Pierre-BĂ©nite | 69495 | France |
Not provided
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| D020022 | Genetic Predisposition to Disease |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D017422 | Sequence Analysis, DNA |
| ID | Term |
|---|---|
| D017421 | Sequence Analysis |
| D005821 | Genetic Techniques |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
DNA analyses will be performed on purified abnormal plasmocytes, obtained from bone marrow aspirates performed during the standard follow-up of patients with multiple myeloma.
|
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D004198 | Disease Susceptibility |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |